ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
446 articles with ImmunoGen Inc.
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results
10/18/2019
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results
-
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
9/29/2019
FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients
-
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
9/29/2019
ImmunoGen, Inc. announced initial safety and overall response data from the Phase 1b FORWARD II triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin® in patients with recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.
-
ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO
9/17/2019
ImmunoGen, Inc. announced that full data and additional exploratory analyses from the Phase 3 FORWARD I study evaluating mirvetuximab soravtansine compared to chemotherapy in women with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress to be held from September 27 to October 1, 2019 in Barcelona, Spain.
-
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
8/2/2019
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2019.
-
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results
7/18/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 2, 2019 to discuss its second quarter operating results.
-
ImmunoGen Announces Completion of Operational Review
6/27/2019
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates
-
Following an operational review, ImmunoGen will prioritize continued development of mirvetuximab, as well as a select portfolio of three earlier-stage product candidates.
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
5/15/2019
ImmunoGen, Inc. announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
-
Good, but Not Good Enough: FDA Urges ImmunoGen to Run Another Phase III Trial for Ovarian Cancer ...
5/15/2019
The FDA told the company that the results from the trial didn’t meet its primary endpoint under the pre-specified statistical analysis plan and the data around the secondary endpoints couldn’t be used to support an accelerated approval application. -
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
5/3/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2019.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
4/18/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019
-
ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
3/1/2019
ImmunoGen, Inc. announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.
-
ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
-
ImmunoGen Announces Multiple Presentations at AACR Annual Meeting
2/27/2019
First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers
-
ImmunoGen Reports Recent Progress and 2018 Operating Results
2/8/2019
Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019
-
ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
1/24/2019
ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results.
-
ImmunoGen Announces Sale of Residual Kadcyla Royalties
1/8/2019
ImmunoGen, Inc. today announced the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla® (ado-trastuzumab emtansine) to OMERS
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference
1/2/2019
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco.